Maravai LifeSciences, providing reagents to researchers, biotherapeutics manufacturers and OEM partners worldwide, recently announced plans to relocate and expand its TriLink BioTechnologies operations with the signing of a lease on a new facility in the Sorrento Valley area of San Diego.
Maravai Expands TriLink BioTech Operation
TriLink will consolidate its San Diego facilities into a new 95,000-square-foot space with an option to expand for future growth. The new facility will house the company’s current local staff of more than 150 and can accommodate growth to more than 350 R&D, commercial and manufacturing employees. The company’s current Good Manufacturing Practice (cGMP) production capabilities will also be relocated, validated and expanded.
Science Exchange, the leading marketplace for outsourced R&D™, announces a collaboration with Reveal Biosciences to offer on-demand access to AI-based pathology services worldwide.
Science Exchange-Reveal Biosciences AI Pathology Collaboration
Reveal Biosciences is a San Diego-based company that’s leading the next generation of quantitative histopathology, combining the latest artificial intelligence (AI) techniques with high-quality histology, immunohistochemistry (IHC) and in situ hybridization (ISH) to generate enhanced data from tissue samples.
Chronic Inflammatory Diseases New Drug Discovery for. Blocking the CMPK2 enzyme may result in new treatments for osteoarthritis, Alzheimer’s disease, Parkinson’s disease, lung cancer and more chronic inflammation disease.
Chronic Inflammatory Diseases New Drug Discovery
Chronic Inflammatory Diseases, inflammation can lead to cancer, Alzheimer’s disease and other conditions. Inflammasomes — protein-based molecular machines — trigger inflammation in response to different signals generated by cell stress, tissue injury or infectious organisms.
San Diego-based Forge Therapeutics, Inc., a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, recently announced a significant collaboration with CARB-X, (Combating Antibiotic Resistant Bacteria Accelerator), the world’s largest public-private partnership focused on funding the advancement of Gram-negative antibiotics. CARB-X selected Forge from a group of 168 international companies and research groups to be one of the first recipients of this novel cost-sharing award. Forge will receive an initial award of $4.8M over 15 months and potentially up to $4M from CARB-X after that period upon achievement of certain milestones. Continue reading “Forge Therapeutics Wins Powered by CARB-X Research Award of $8.8M”